Standout Papers

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activatin... 2004 2026 2011 2018 3.5k
  1. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling (2007)
    Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Science
  2. Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival (2004)
    Junichi Takamizawa, Hiroyuki Konishi et al. Cancer Research
  3. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer (2004)
    Takayuki Kosaka, Yasushi Yatabe et al. Cancer Research
  4. EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors (2010)
    Young Lim Choi, Manabu Soda et al. New England Journal of Medicine
  5. Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence (2005)
    Tetsuya Mitsudomi, Takayuki Kosaka et al. Journal of Clinical Oncology
  6. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. (1998)
    Toyoaki Hida, Yasushi Yatabe et al. PubMed
  7. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial (2022)
    Hisashi Saji, Morihito Okada et al. The Lancet
  8. Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations (2008)
    Seiji Yano, Wei Wang et al. Cancer Research
  9. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study (2016)
    Glenwood Goss, Chun‐Ming Tsai et al. The Lancet Oncology
  10. A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201) (2011)
    Kenji Suzuki, Teruaki Koike et al. Journal of Thoracic Oncology
  11. Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial (2019)
    Kenji Suzuki, Hisashi Saji et al. Journal of Thoracic and Cardiovascular Surgery
  12. A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer (2020)
    Kenji Suzuki, Shun‐ichi Watanabe et al. Journal of Thoracic and Cardiovascular Surgery
  13. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments (2021)
    T. Koga, Kenichi Suda et al. Journal of Thoracic Oncology

Immediate Impact

5 by Nobel laureates 18 from Science/Nature 156 standout
Sub-graph 1 of 14

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
A view on drug resistance in cancer
2019 StandoutNature
57 intermediate papers

Works of Tetsuya Mitsudomi being referenced

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib
2006
and 30 more

Author Peers

Author Last Decade Papers Cites
Tetsuya Mitsudomi 22217 17840 14384 530 35.9k
Jean‐Charles Soria 12561 19265 12792 675 34.0k
Stéphane Oudard 26909 13527 16290 611 37.9k
Vincent A. Miller 30167 29326 15829 476 44.8k
Ronald M. Bukowski 19691 13215 17507 454 33.5k
Yasushi Yatabe 14927 14366 11845 632 31.1k
Fortunato Ciardiello 11605 21501 13119 626 33.5k
Richard Pazdur 9902 19104 10270 582 36.2k
Ignacio I. Wistuba 12081 15981 16436 676 34.9k
Bruce E. Johnson 28871 29340 20418 411 49.7k
Robert A. Figlin 25082 11928 21802 467 37.4k

All Works

Loading papers...

Rankless by CCL
2026